Clinical obesity status outperformed BMI in surgery candidates

What happened

A multicenter study published August 11, 2026 in JAMA Network Open applied the new clinical-versus-preclinical obesity definitions to 2,316 candidates for metabolic and bariatric surgery and found that about three quarters met criteria for full clinical obesity. Francesco Rubino of King's College London led the work, which audited adults undergoing primary gastric bypass or sleeve gastrectomy at four high-volume tertiary centers: King's College Hospital in the UK, Hospital del Mar in Barcelona, the University Hospital of Lille in France, and Hospital Alemão Oswaldo Cruz in São Paulo.

The framework comes from the Lancet Diabetes & Endocrinology Commission on Clinical Obesity, which proposed in January 2025 that obesity be diagnosed as clinical obesity when excess adiposity is causing measurable organ damage, and preclinical obesity when organ function is preserved despite excess fat. Applied to surgical candidates, 73.8 percent had clinical obesity and 26.2 percent had preclinical obesity. Clinical obesity was the majority category everywhere, ranging from 62.7 percent of the Brazilian cohort to 79.3 percent of the UK cohort.

The central finding is what BMI did not show. Mean BMI was statistically indistinguishable between the two groups within every center; in the UK cohort it averaged 47.5 with clinical obesity against 48.5 with preclinical obesity. Yet patients with clinical obesity were roughly a decade older on average across all centers, had higher anesthesiology risk classifications, higher Charlson comorbidity scores where measured, and higher Framingham cardiovascular risk estimates.

Operative consequences appeared in the one cohort with usable complication data: major 30-day complications, Clavien-Dindo grade three or higher, occurred in 4.0 percent of clinical-obesity patients versus 1.1 percent of preclinical patients in the French cohort. Weight-loss outcomes ran slightly lower for the clinical group at 12 and 24 months, differences of roughly two to four percentage points where statistically significant. Rubino said future surgical studies and registries should systematically record each patient's clinical or preclinical status so outcomes can be interpreted in the right context.

What it means

Two patients standing in the same BMI eligibility band can carry very different disease. That is the entire argument of the study, demonstrated inside a population selected by BMI in the first place. The distinction reframes what surgery is for: treatment of established disease for someone with clinical obesity, versus reduction of future risk for someone with preclinical obesity. Those are different conversations about urgency, expected benefit, and how success should be judged.

It also matters for reading outcome data. If clinical status predicts both complication rates and weight-loss trajectories, then programs treating sicker populations will look worse on raw complication tables and weight benchmarks even when delivering equivalent care. Registries that ignore the clinical-versus-preclinical split will keep mixing these populations together.

For patients, the practical takeaway is that BMI alone says little about whether excess fat is actively harming organs. A thorough assessment of organ function, not just a height-weight chart, is what distinguishes the two situations, and that assessment may shape prioritization and follow-up intensity going forward.

What it does not mean

This was a retrospective audit of routinely collected data, not a prospective diagnostic study. Organ dysfunction was classified from existing diagnoses, labs, imaging, and medication records using pragmatic adjudication agreed after the fact, so some misclassification is certain. The authors themselves flag the risk of over-attribution: retrospective coding cannot prove that every recorded dysfunction was actually caused by adiposity, which the commission's definition requires, so the 74 percent figure may overestimate true clinical obesity.

Complication findings rest on thin ground: only the French cohort showed a statistically significant difference, UK and Spanish differences were small and non-significant, and Brazilian complication data were unavailable. The study also could not confirm excess adiposity with commission-recommended body measurements for patients under BMI 40, and it measured no outcomes beyond two years. Nothing here changes surgical eligibility criteria today, and the competing view that the framework is not yet ready to triage treatment remains live in the literature. Decisions about surgery belong to patients and their clinical teams, not to a classification label alone.